scholarly journals Sitafloxacin Expresses Potent Anti-Mycobacterium abscessus Activity

2022 ◽  
Vol 12 ◽  
Author(s):  
Siyuan He ◽  
Qi Guo ◽  
Lan Zhao ◽  
Liyun Xu ◽  
Junsheng Fan ◽  
...  
Keyword(s):  
Antimicrobial Susceptibility ◽  
Susceptibility Testing ◽  
Mycobacterium Abscessus ◽  
Therapeutic Options ◽  
Intracellular Growth ◽  
Bacteriostatic Effect ◽  
Checkerboard Assay ◽  
Reference Strains ◽  
New Strategies

Therapeutic options for treating Mycobacterium abscessus infections are extremely limited; quinolones are important. The in vitro anti-M. abscessus activities of nine quinolones, emphasizing sitafloxacin, were investigated. Antimicrobial susceptibility testing was performed on 10 non-tuberculous mycobacterium reference strains and 194 clinical, M. abscessus isolates. The activity of sitafloxacin against intracellular M. abscessus residing within macrophages was also evaluated. A checkerboard assay was conducted to determine synergy between sitafloxacin and 10 clinically important antibiotics. Among the nine quinolones tested, sitafloxacin exhibited the greatest anti-M. abscessus activity with MIC50 and MIC90 of 1 and 2 mg/L, respectively. Sitafloxacin exerted a bacteriostatic effect on M. abscessus and inhibited the intracellular growth of M. abscessus at concentrations equivalent to clarithromycin. No antagonism between sitafloxacin and 10 clinically important anti-M. abscessus antibiotics was evident. In summary, sitafloxacin exhibited a significant advantage relative to other quinolones in inhibiting the growth of M. abscessus in vitro, suggesting the potential inclusion of sitafloxacin in new strategies to treat M. abscessus infections.

scholarly journals In Vitro Antimicrobial Susceptibility of Mycobacterium abscessus in Korea

2008 ◽  
Vol 23 (1) ◽  
pp. 49 ◽  
Author(s):  
Sunghoon Park ◽  
Shinok Kim ◽  
Eun Mi Park ◽  
Hojoong Kim ◽  
O Jung Kwon ◽  
...  
Keyword(s):  
Antimicrobial Susceptibility ◽  
Mycobacterium Abscessus

scholarly journals Gentamicin susceptibility among a sample of multi-drug resistantNeisseria gonorrhoeaeisolates in India

2016 ◽  
pp. AAC.01907-16 ◽  
Author(s):  
Manju Bala ◽  
Vikram Singh ◽  
Aradhana Bhargava ◽  
Monika Kakran ◽  
Naveen Chandra Joshi ◽  
...  
Keyword(s):  
Effective Treatment ◽  
Treatment Outcomes ◽  
Treatment Option ◽  
Antimicrobial Susceptibility ◽  
Susceptibility Testing ◽  
Dual Therapy ◽  
Clinical Treatment ◽  
Antimicrobial Susceptibility Testing ◽  
Effective Treatment Option

Antimicrobial susceptibility testing of 258N. gonorrhoeaeisolates by Etest determined that 60.1% were MDR while 5% strains had decreased susceptibility to currently recommended extended-spectrum cephalosporins (ESCs). Among these, 84.5% MDR and 76.9% strains having decreased susceptibility to ESCs were susceptible to gentamicin. No MDR isolate was resistant to gentamicin. Thesein vitroresults suggest that gentamicin might be an effective treatment option for the MDR strains and in dual therapy for gonorrhea. However, further research regarding the clinical treatment outcomes is essential.

In vitro susceptibility of Mycobacterium abscessus complex and feasibility of standardizing treatment regimens

2020 ◽  
Author(s):  
Ka Lip Chew ◽  
Sophie Octavia ◽  
Joelle Go ◽  
Sally Ng ◽  
Yit Er Tang ◽  
...  
Keyword(s):  
Retrospective Review ◽  
Susceptibility Testing ◽  
Mycobacterium Abscessus ◽  
In Vitro Activity ◽  
Broth Microdilution ◽  
In Vitro Susceptibility ◽  
Treatment Regimens ◽  
Mycobacterium Abscessus Complex ◽  
Additional Testing

Abstract Objectives To determine the in vitro susceptibility of members of the Mycobacterium abscessus complex to routinely tested antibiotics and to an extended antibiotic panel. Methods Non-duplicate isolates for which susceptibility testing results were available were included in this study. Retrospective laboratory records were reviewed, including tigecycline susceptibility results, and testing was performed with additional drugs, including vancomycin, dalbavancin, telavancin, oritavancin, rifabutin, delafloxacin, eravacycline, clofazimine and bedaquiline using broth microdilution (Sensititre, Thermo Fisher). Results A total of 218 M. abscessus complex isolates were included for retrospective review, of which 151 were respiratory isolates. Of these 218 isolates, 211 were available for additional testing with the extended antibiotic panel. Of these, 146 were respiratory isolates. One isolate had a vancomycin MIC of 2 mg/L and MICs of all other isolates were >8 mg/L. All isolates had MICs of >8 mg/L for oritavancin, dalbavancin and telavancin. One isolate had a delafloxacin MIC of 4 mg/L and MICs of all other isolates were >8 mg/L. The MIC50/MIC90s of rifabutin, tigecycline, eravacycline, clofazimine and bedaquiline were 16/32, 0.5/1, 0.12/0.25, 0.12/0.25 and 0.06/0.12 mg/L, respectively. Conclusions In vitro activity was demonstrated for clofazimine, bedaquiline and eravacycline, indicating potential for inclusion as standardized therapy for M. abscessus complex infections.

scholarly journals Impact of sarA on Antibiotic Susceptibility of Staphylococcus aureus in a Catheter-Associated In Vitro Model of Biofilm Formation

2009 ◽  
Vol 53 (6) ◽  
pp. 2475-2482 ◽  
Author(s):  
Elizabeth C. Weiss ◽  
Horace J. Spencer ◽  
Sonja J. Daily ◽  
Brian D. Weiss ◽  
Mark S. Smeltzer
Keyword(s):  
Staphylococcus Aureus ◽  
Clinical Isolate ◽  
Antimicrobial Susceptibility ◽  
Antibiotic Susceptibility ◽  
Biofilm Formation ◽  
In Vitro Model ◽  
Susceptibility Testing ◽  
Specific Context ◽  
Vitro Model

ABSTRACT Mutation of the staphylococcal accessory regulator (sarA) in Staphylococcus aureus limits but does not abolish the capacity of the organism to form a biofilm. As a first step toward determining whether this limitation is therapeutically relevant, we carried out in vitro studies comparing the relative susceptibility of an S. aureus clinical isolate (UAMS-1) and its isogenic sarA mutant (UAMS-929) in the specific context of a catheter-associated biofilm. The antibiotics tested were daptomycin, linezolid, and vancomycin, all of which were evaluated by using concentrations based on the MIC defined as the breakpoint for a susceptible strain of S. aureus (≤1.0, ≤2.0, and ≤4.0 μg/ml for daptomycin, vancomycin, and linezolid, respectively). Mutation of sarA had no significant impact on the MIC of UAMS-1 for any of the targeted antibiotics, as defined by Etest antimicrobial susceptibility testing. However, mutation of sarA did result in a significant increase in antimicrobial susceptibility to all targeted antibiotics when they were tested in the specific context of a biofilm. Additionally, whether susceptibility was assessed by using UAMS-1 or its sarA mutant, daptomycin was found to be more effective against established S. aureus biofilms than either linezolid or vancomycin.

scholarly journals Etest Cannot Be Recommended forIn VitroSusceptibility Testing of Mucorales

2015 ◽  
Vol 59 (6) ◽  
pp. 3663-3665 ◽  
Author(s):  
Rita Caramalho ◽  
Elisabeth Maurer ◽  
Ulrike Binder ◽  
Ricardo Araújo ◽  
Somayeh Dolatabadi ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Antimicrobial Susceptibility ◽  
Active Drug ◽  
Susceptibility Testing ◽  
Antifungal Susceptibility ◽  
Antifungal Susceptibility Testing ◽  
Broth Microdilution ◽  
European Committee ◽  
Susceptibility Patterns

ABSTRACTAmphotericin B and posaconazole susceptibility patterns were determined for the most prevalent Mucorales, following EUCAST (European Committee on Antimicrobial Susceptibility Testing) broth microdilution guidelines. In parallel, Etest was performed and evaluated against EUCAST. The overall agreement of MICs gained with Etest and EUCAST was 75.1%; therefore, Etest cannot be recommended for antifungal susceptibility testing of Mucorales. Amphotericin B was the most active drug against Mucorales speciesin vitro, while the activities of posaconazole were more restricted.

scholarly journals A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro

2021 ◽  
Author(s):  
Qi Guo ◽  
Liyun Xu ◽  
Fusheng Tan ◽  
Yongjie Zhang ◽  
Junsheng Fan ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Mycobacterium Abscessus ◽  
Clinical Isolates ◽  
Novel Approach ◽  
Reference Strains

An evaluation of the anti- M. abscessus activity expressed by a novel oxazolidinone, contezolid (MRX-I), toward 12 reference strains and 194 clinical isolates was conducted. Contezolid was active against M. abscessus in vitro , and comparable to the anti- M. abscessus effects of linezolid both extracellularly and intracellularly. Contezolid did not antagonize the most frequently used anti- M. abscessus drugs nor did pre-exposure to contezolid induce drug resistance. These results provide a novel approach to treating M. abscessus infections.

Sign in / Sign up

Export Citation Format

Share Document